Breast cancer resistance protein (BCRP)/ATP-binding cassette subfamily G member 2
(ABCG2) is an ATP-binding cassette (ABC) transporter identified as a molecular cause of …

Solute carrier (SLC) family transporters utilize an electrochemical potential difference or an
ion gradient generated by primary active transporters for transporting their substrates across …

Chronic myeloid leukemia (CML) is genetically characterized by the Philadelphia (Ph)
chromosome, formed through a reciprocal translocation between chromosomes 9 and 22 …

The historical phasing concept of drug metabolism and elimination was introduced to
comprise the two phases of metabolism: phase I metabolism for oxidations, reductions and …

Many solute carrier transporters that interact with anticancer agents and contribute to their
pharmacokinetics have been shown to be differentially upregulated in cancer cells as a …

The use of small molecules became one key cornerstone of targeted anti-cancer therapy.
Among them, tyrosine kinase inhibitors (TKIs) are especially important, as they were the first …

Chronic myeloid leukemia (CML) has long served as a paradigm for generating new insights
into the cellular origin, pathogenesis and improved approaches to treating many types of …

Tyrosine kinase inhibitors (TKIs) are being increasingly used to treat various malignancies.
Although they were designed to target aberrant tyrosine kinases, they are also intimately …

Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and
imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML) in chronic …

BCR-ABL overexpression and stem cell quiescence supposedly contribute to the failure of
imatinib mesylate (IM) to eradicate chronic myeloid leukemia (CML). However, BCR-ABL …